Boehringer Ingelheim and Cue Biopharma Collaborate to Develop Innovative B Cell Depletion Therapy for Autoimmune Diseases
On April 14, 2025, Boehringer Ingelheim, a leading research-driven pharmaceutical company based in Ingelheim, Germany, and Cue Biopharma, Inc., a clinical-stage biopharmaceutical company headquartered in Boston, announced a strategic research collaboration and license agreement. This collaboration aims to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a groundbreaking B cell depletion therapy for autoimmune diseases.
About Cue Biopharma and CUE-501
Cue Biopharma is a pioneering biotech company specializing in the development of a novel class of therapeutic biologics. They focus on selectively engaging and modulating disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases. CUE-501 is an investigational product candidate designed to selectively target and deplete B cells, which are known to play a critical role in the pathogenesis of various autoimmune diseases.
Terms of the Collaboration and License Agreement
Under the terms of the agreement, Boehringer Ingelheim will provide financial support to Cue Biopharma for the ongoing development of CUE-501. In return, Boehringer Ingelheim will receive an exclusive license to develop and commercialize the therapy worldwide, excluding certain territories. Cue Biopharma will continue to be responsible for the ongoing research and development activities related to CUE-501.
Impact on Patients and the World
For patients suffering from autoimmune diseases, this collaboration represents a significant step forward in the development of novel and effective treatments. B cell depletion therapies have shown promise in treating various autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. By selectively targeting and depleting B cells, CUE-501 aims to provide a more targeted and potentially safer approach to current B cell depletion therapies.
Global Reach and Significance
The strategic collaboration between Boehringer Ingelheim and Cue Biopharma extends beyond the laboratory. With Boehringer Ingelheim’s global reach and expertise in developing and commercializing innovative therapeutic solutions, this collaboration has the potential to significantly impact the lives of millions of people worldwide who are diagnosed with autoimmune diseases each year.
Conclusion
The strategic research collaboration and license agreement between Boehringer Ingelheim and Cue Biopharma represents an exciting step forward in the development of innovative and targeted therapies for autoimmune diseases. With Cue Biopharma’s novel approach to selectively engaging and modulating disease-specific T cells and Boehringer Ingelheim’s global reach and expertise, this collaboration has the potential to bring meaningful improvements to the lives of patients suffering from various autoimmune diseases.
- Boehringer Ingelheim and Cue Biopharma announce strategic research collaboration and license agreement
- Collaboration aims to develop and commercialize Cue Biopharma’s CUE-501 product candidate
- CUE-501 is a selective B cell depletion therapy for autoimmune diseases
- Boehringer Ingelheim to provide financial support and receive exclusive license
- Collaboration has the potential to significantly impact the lives of millions of patients worldwide
